Why the Certificate of Analysis Is Your First Quality Gate
Before a research peptide ever enters an assay, its Certificate of Analysis (COA) provides the only objective record of what the supplier has verified about that specific batch. A COA is not a marketing document; it is a technical summary of analytical testing performed on a discrete lot of synthesised peptide. Understanding every field on that document allows researchers to judge fitness-for-purpose, troubleshoot unexpected results, and maintain rigorous experimental reproducibility. This guide walks through each standard COA section and explains what the data actually mean.
Lot and Batch Identification
At the top of any legitimate COA you will find the lot number (sometimes called batch number) alongside the peptide's catalogue reference and full sequence. These identifiers tie every analytical result to a single, traceable production run. Before reading any data, confirm that the lot number on the vial label matches the lot number on the COA exactly. A mismatch—however minor—means the analytical data cannot be assumed to apply to the material in hand. Reputable suppliers also include the synthesis date and the analysis date, which together indicate how fresh the data are relative to storage.
Purity: The Most Scrutinised Figure
Purity is almost universally expressed as a percentage and is determined by reverse-phase high-performance liquid chromatography (RP-HPLC). The instrument separates components by hydrophobicity, and the detector—typically a UV diode-array set at 214 nm—reports the relative peak areas. Purity is then calculated as the area of the target peptide peak divided by the total integrated area of all detected peaks, multiplied by 100.
Key points to understand about HPLC purity:
- Threshold conventions vary by application. Many biochemical binding assays accept ≥95% purity, whereas structural studies or quantitative cell-based work frequently demand ≥98%. Know your assay requirements before purchasing.
- UV detection at 214 nm measures peptide bonds, not total mass. Small organic impurities lacking peptide bonds may not be captured, which is one reason HPLC purity alone is insufficient as a sole quality metric.
- The chromatogram itself matters. A single, symmetrical peak with a well-defined baseline is preferable to a broad or shouldered peak even if the stated purity figure is the same. Request the raw chromatogram if only the percentage is provided.
Mass Spectrometry: Confirming Molecular Identity
Where HPLC answers "how pure," mass spectrometry (MS) answers "is this the correct molecule." The COA should report the theoretical molecular weight calculated from the amino acid sequence and any modifications, alongside the observed m/z (mass-to-charge ratio) value from the instrument.
Most peptide suppliers use electrospray ionisation (ESI-MS) or matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) instruments. Because peptides acquire multiple proton charges during ESI, you will often see a series of multiply charged ions (e.g., [M+2H]²⁺, [M+3H]³⁺). The software deconvolutes these to report a single average or monoisotopic mass. A match within ±0.5 Da (for average mass instruments) or ±0.1 Da (for high-resolution instruments) confirms that the correct peptide was synthesised.
A discrepancy between theoretical and observed mass is diagnostically useful. Common explanations include:
- Incomplete deprotection of side-chain protecting groups used during solid-phase synthesis
- Oxidation of methionine or cysteine residues during storage or handling
- Incorrect sequence synthesis, detectable as a mass shift corresponding to a missing or substituted residue
- Presence of counter-ions (e.g., TFA adducts) that shift the observed mass
If MS data are absent from a COA entirely, treat the product with caution. Identity confirmation is a non-negotiable minimum for any quantitative research application.
Counter-Ion and Salt Form
Standard solid-phase Fmoc synthesis uses trifluoroacetic acid (TFA) extensively in deprotection and cleavage steps. Unless specifically removed, TFA remains as the counter-ion of the final peptide salt. The COA should state the salt form, typically expressed as the peptide trifluoroacetate or, if ion-exchange purification has been applied, as the acetate or hydrochloride salt.
This matters because TFA is cytotoxic at concentrations achievable in cell-based assays and can also interfere with certain enzymatic and biophysical assays. Researchers running mammalian cell experiments should verify that TFA has been removed or exchanged, or perform their own exchange step. The net peptide content calculation (see below) is also affected by the salt form.
Net Peptide Content and Moisture
The mass printed on a vial label is the gross weight of the lyophilised material, which includes the peptide itself, residual water, counter-ions, and traces of solvent. The net peptide content (NPC) figure—sometimes also called peptide content or corrected weight—represents the actual mass fraction attributable to the target peptide.
NPC is determined by quantitative amino acid analysis (AAA) or nitrogen/carbon elemental analysis. A peptide supplied at 10 mg gross weight with an NPC of 75% contains, in practice, 7.5 mg of active peptide. Failing to account for NPC leads to systematic errors in stock solution preparation and dose-response calculations. Always use NPC when preparing molar concentrations for quantitative experiments.
Amino Acid Analysis
Some COAs, particularly for longer or more complex sequences, include amino acid analysis (AAA) results. After complete acid hydrolysis of the peptide, individual amino acids are separated and quantified by HPLC with pre- or post-column derivatisation. The molar ratios of each amino acid are compared to the expected ratios from the sequence. AAA provides orthogonal identity confirmation and is especially valuable when MS data are ambiguous due to isobaric sequences.
Additional Analytical Data to Look For
Depending on the peptide complexity and supplier capability, a COA may include:
- Endotoxin testing (LAL assay): Critical if the peptide will be used in any cell-based assay sensitive to lipopolysaccharide contamination.
- Sterility testing: Relevant for aseptic handling protocols, though not a regulatory requirement for research-grade material.
- Solubility recommendations: Empirically tested solubility data in defined solvents help researchers avoid aggregation artefacts.
- Storage conditions: Stability data or recommended temperature and atmosphere (e.g., argon blanketing for cysteine-containing peptides) inform proper lot management.
Putting It All Together: A Pre-Experiment Checklist
Before committing a peptide lot to experiments, work through the following sequence using the COA:
- Confirm the lot number matches the vial label.
- Verify that HPLC purity meets the threshold required by your specific assay.
- Check that the observed MS mass matches the theoretical value within instrument tolerance.
- Identify the counter-ion and assess whether it presents interference risk.
- Record the net peptide content and use it for all stock calculations.
- Note the analysis date and compare it to your intended use window.
- File the COA with your experimental records to support reproducibility and publication requirements.
A well-documented COA, read critically, transforms an anonymous white powder into characterised material whose behaviour can be rationally interpreted. Skipping this step is a frequent and avoidable source of irreproducible results in peptide research.
For research use only. All information presented here is intended solely for in-vitro laboratory research applications. This article does not constitute medical advice, clinical guidance, or any recommendation for use in humans or animals.